Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS. van der Heijde D, et al. Among authors: koenig as. Rheumatology (Oxford). 2012 Oct;51(10):1894-905. doi: 10.1093/rheumatology/kes142. Epub 2012 Jul 6. Rheumatology (Oxford). 2012. PMID: 22772319 Clinical Trial.
Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R. Pavelka K, et al. Among authors: koenig as. Clin Rheumatol. 2013 Sep;32(9):1275-81. doi: 10.1007/s10067-013-2240-4. Epub 2013 May 11. Clin Rheumatol. 2013. PMID: 23666316 Clinical Trial.
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Smolen JS, et al. Among authors: koenig as. Arthritis Res Ther. 2018 Jan 16;20(1):8. doi: 10.1186/s13075-017-1484-9. Arthritis Res Ther. 2018. PMID: 29338762 Free PMC article. Clinical Trial.
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS. Emery P, et al. Among authors: koenig as. Ann Rheum Dis. 2012 Jun;71(6):989-92. doi: 10.1136/annrheumdis-2011-201066. Epub 2012 Mar 8. Ann Rheum Dis. 2012. PMID: 22402142
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B. Smolen JS, et al. Among authors: koenig as. Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17. Lancet. 2013. PMID: 23332236 Clinical Trial.
56 results